Table 2.
Number of cases and ROR (95% CI) of each NSAID-induced lower gastrointestinal tract injury adverse event reported in JADER.
| LGTI | Other AE | LGTI (%) | ROR | 95% CI | |
|---|---|---|---|---|---|
| [I] | |||||
| Loxoprofen (+) | 236 | 23,026 | 1.02 | 1.61 | 1.40–1.84 |
| Loxoprofen (−) | 2271 | 357,251 | 0.63 | ||
| [III] | |||||
| Diclofenac (+) | 274 | 9395 | 2.91 | 4.84 | 4.26–5.50 |
| Diclofenac (−) | 2233 | 370,882 | 0.60 | ||
| [II] | |||||
| Loxoprofen | |||||
| Rebamipide (+) | 36 | 6066 | 0.59 | 0.50 | 0.35–0.71 |
| Rebamipide (−) | 200 | 16,960 | 1.17 | ||
| [IV] | |||||
| Diclofenac | |||||
| Rebamipide (+) | 21 | 1518 | 1.38 | 0.43 | 0.27–0.67 |
| Rebamipide (−) | 253 | 7877 | 3.21 | ||
Lower gastrointestinal tract injury of single-drug NSAIDs [I], [III]. Lower gastrointestinal tract injury with concomitant use of rebamipide and NSAIDs [II], [IV].
LGTI lower gastrointestinal tract injury, AE adverse event.